Orchard Therapeutics

176 articles with Orchard Therapeutics

• Orchard Therapeutics Completes ADS Ratio Change

  3/10/2023

  Orchard Therapeutics, a global gene therapy leader, announced that the Company’s previously disclosed change to its American Depositary Share to ordinary share ratio has been made effective.

• Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results

  3/6/2023

  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced business updates along with its financial results for the quarter and year ended December 31, 2022.

• Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million

  3/6/2023

  Orchard Therapeutics announced that it has entered into a securities purchase agreement for the sale of ordinary shares and warrants in a private placement that could bring in up to $188 million at increasing valuations following the achievement of U.S. regulatory milestones for OTL-200 for metachromatic leukodystrophy.

• Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023

  3/3/2023

  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences.

• Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden

  2/27/2023

  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT) Council which will result in reimbursed access to Libmeldy ® (atidarsagene autotemcel) for all metachromatic leukodystrophy (MLD) patients who fall within the scope of the European marketing authorization in Sweden.

• Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™

  2/24/2023

  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced long-term results from an updated integrated analysis of 39 patients with metachromatic leukodystrophy (MLD) treated with investigational OTL-200 in the clinical development program.

• Orchard Therapeutics Announces Proposed ADS Ratio Change

  2/10/2023

  Orchard Therapeutics, a global gene therapy leader, announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares, nominal value £0.10 per share, from the current ADS Ratio of one ADS to one ordinary share to a new ADS Ratio of one ADS to ten ordinary shares.

• Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLD Symposium

  2/8/2023

  Orchard Therapeutics today announced a series of presentations from across its neurometabolic portfolio will be featured at the 19th Annual WORLD Symposium taking place February 22-26, 2023, in Orlando, Florida.

• Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

  1/9/2023

  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced recent commercial and regulatory accomplishments and outlined key 2023 milestones, highlighting the strong potential of its hematopoietic stem cell (HSC) gene therapy platform to drive value for patients, providers and shareholders.

• Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IHGlobal registrational trial expected to commence in the second half of 2023

  1/5/2023

  Orchard Therapeutics, a global gene therapy leader, announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for OTL-203, a hematopoietic stem cell gene therapy being developed for the treatment of the Hurler subtype of mucopolysaccharidosis type I.

• Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA

  12/12/2022

  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced early clinical findings, including the first neurocognitive results, from its ongoing proof-of-concept (PoC) study of OTL-201, an investigational hematopoietic stem cell (HSC) gene therapy being developed for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA), also known as Sanfilippo syndrome type A.

• Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

  12/1/2022

  Orchard Therapeutics, a global gene therapy leader, announced its marketing authorization application for Libmeldy® has been accepted for evaluation by the Swiss Agency for Therapeutic Products for the potential treatment of eligible patients with early-onset metachromatic leukodystrophy.

• Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights

  11/14/2022

  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced recent business highlights along with its financial results for the quarter ended September 30, 2022.

• Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022

  11/8/2022

  Orchard Therapeutics, a global gene therapy leader, announced that members of the management team will present at the following investor conferences.

• Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results

  11/7/2022

  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Monday, November 14, 2022, at 8:00 a.m. EST to review business updates and its third quarter 2022 financial results.

• Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022

  11/3/2022

  Orchard Therapeutics announced early clinical findings from its ongoing proof-of-concept study of investigational OTL-201 in MPS-IIIA will be featured in an oral presentation at the 64th American Society of Hematology Annual Meeting & Exposition, taking place December 10-13, 2022, in New Orleans.

• Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas

  10/10/2022

  Orchard Therapeutics today announced multiple presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh.

• Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology

  7/26/2022

  Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology.

• 

  Following bluebird's FDA Win, 4 Companies Aim High with New Gene Therapies

  6/13/2022

  BioSpace looks at several companies developing new gene therapies in the wake of the FDA recommending two of bluebird bio’s lentiviral vector gene therapies.

• Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress

  5/12/2022

  Orchard Therapeutics, a global gene therapy leader, announced recent business highlights along with its financial results for the quarter ended March 31, 2022.